Publications

Journal Article
Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.
Ppublish 1171 citations
Electronic publication date
February 22, 2012

View on Pubmed.gov 21911655 | View on doi.org 10.1001/archneu...

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Search for publications in this journal Arch Neurol - 69(1):29-38

Abstract

OBJECTIVE

To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment or Alzheimer disease (AD).

DESIGN

Randomized, double-blind, placebo-controlled trial.

SETTING

Clinical research unit of a Veterans Affairs medical center.

PARTICIPANTS

The intent-to-treat sample consisted of 104 adults with amnestic mild cognitive impairment (n = 64) or mild to moderate AD (n = 40). Intervention  Participants received placebo (n = 30), 20 IU of insulin (n = 36), or 40 IU of insulin (n = 38) for 4 months, administered with a nasal drug delivery device (Kurve Technology, Bothell, Washington).

MAIN OUTCOME MEASURES

Primary measures consisted of delayed story recall score and the Dementia Severity Rating Scale score, and secondary measures included the Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) score and the Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL) scale. A subset of participants underwent lumbar puncture (n = 23) and positron emission tomography with fludeoxyglucose F 18 (n = 40) before and after treatment.

RESULTS

Outcome measures were analyzed using repeated-measures analysis of covariance. Treatment with 20 IU of insulin improved delayed memory (P < .05), and both doses of insulin (20 and 40 IU) preserved caregiver-rated functional ability (P < .01). Both insulin doses also preserved general cognition as assessed by the ADAS-cog score for younger participants and functional abilities as assessed by the ADCS-ADL scale for adults with AD (P < .05). Cerebrospinal fluid biomarkers did not change for insulin-treated participants as a group, but, in exploratory analyses, changes in memory and function were associated with changes in the Aβ42 level and in the tau protein-to-Aβ42 ratio in cerebrospinal fluid. Placebo-assigned participants showed decreased fludeoxyglucose F 18 uptake in the parietotemporal, frontal, precuneus, and cuneus regions and insulin-minimized progression. No treatment-related severe adverse events occurred.

CONCLUSIONS

These results support longer trials of intranasal insulin therapy for patients with amnestic mild cognitive impairment and patients with AD. Trial Registration  clinicaltrials.gov Identifier: NCT00438568.

References

J Neurosci. 2007 Dec 12;27(50):13635-48

Neurobiol Learn Mem. 2010 May;93(4):546-53

Neuroimage. 2010 Jun;51(2):654-64

Neuroepidemiology. 2008;30(1):58-69

Cited by 1171 citations (total)

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.

Electronic publication date May 19, 2012

Search for publications in this journal Neurobiol Dis

Zhongwu Liu [...] Michael Chopp et al.

As a thrombolytic agent, application of recombinant tissue plasminogen activator (tPA) to ischemic stroke is limited by the narrow time...

Journal Article Comment

Alzheimer’s disease: the new promise.

Electronic publication date July 7, 2012

Search for publications in this journal J Clin Invest

Warren J Strittmatter

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances